OTCPK:BIQL.F

Stock Analysis Report

Executive Summary

Bioquell plc designs, manufactures, and supplies bio-decontamination and containment equipment, and related products and services in the United Kingdom and internationally.

Snowflake

Fundamentals

Flawless balance sheet with solid track record.

Risks

  • Bioquell is not covered by any analysts.

Similar Companies

Share Price & News

How has Bioquell's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:BIQL.F

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

n/a

OTCPK:BIQL.F

9.7%

US Medical Equipment

1.9%

US Market

No trading data on BIQL.F.

No trading data on BIQL.F.


Share holder returns

BIQL.FIndustryMarket
7 Day0%1.5%0.8%
30 Day0%0.7%3.4%
90 Day21.6%2.4%2.1%
1 Yearn/a10.6%9.7%4.2%1.9%
3 Year250.7%250.7%70.2%65.0%46.7%37.2%
5 Year221.9%221.9%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Bioquell's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bioquell undervalued based on future cash flows and its price relative to the stock market?

42.84x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Bioquell's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Bioquell's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Bioquell is good value based on earnings compared to the US Medical Equipment industry average.

Bioquell is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Bioquell, we can't assess if its growth is good value.


Price Based on Value of Assets

Bioquell is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Bioquell expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

2.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Bioquell is high growth as no revenue estimate data is available.

Bioquell's earnings are expected to grow by 2.8% yearly, however this is not considered high growth (20% yearly).

Unable to compare Bioquell's revenue growth to the United States of America market average as no estimate data is available.

Bioquell's earnings growth is positive but not above the United States of America market average.

Bioquell's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Bioquell will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Bioquell performed over the past 5 years?

9.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Bioquell's year on year earnings growth rate has been positive over the past 5 years.

Bioquell's 1-year earnings growth exceeds its 5-year average (146% vs 9%)

Bioquell's earnings growth has exceeded the US Medical Equipment industry average in the past year (146% vs 11.7%).


Return on Equity

Bioquell has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Bioquell used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Bioquell has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Bioquell's financial position?


Financial Position Analysis

Bioquell is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Bioquell's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Bioquell has no debt.

Bioquell has no debt compared to 5 years ago when it was 3.4%.

Bioquell has no debt, it does not need to be covered by operating cash flow.

Bioquell has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Bioquell has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Bioquell's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Bioquell's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Bioquell's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Bioquell has not reported any payouts.

Unable to verify if Bioquell's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Bioquell has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Bioquell's salary, the management and board of directors tenure and is there insider trading?

2.4yrs

Average management tenure


CEO

Bioquell has no CEO, or we have no data on them.


Management Age and Tenure

2.4yrs

Average Tenure

55yo

Average Age

The tenure for the Bioquell management team is about average.


Board Age and Tenure

5.5yrs

Average Tenure

60yo

Average Age

The tenure for the Bioquell board of directors is about average.


Insider Trading

No 3 month insider trading information.


Recent Insider Transactions

SellUK£184,38305 Dec 18
J.P. Morgan Asset Management, Inc.
EntityCompany
Shares25,000
Max PriceUK£7.38

Ownership Breakdown


Management Team

  • Ian Johnson (64yo)

    Executive Chairman

    • Tenure: 2.4yrs
    • Compensation: UK£211.00k
  • Michael Roy Roller (53yo)

    Group Finance Director & Director

    • Tenure: 4.8yrs
    • Compensation: UK£223.00k
  • Jay LeCoque (55yo)

    Commercial Director & Executive Director

    • Tenure: 2.4yrs
    • Compensation: UK£80.00k
  • Georgina Pope

    Secretary

    • Tenure: 0yrs

Board Members

  • Simon Constantine (60yo)

    Non-Executive Director

    • Tenure: 19.2yrs
    • Compensation: UK£30.00k
  • Ian Johnson (64yo)

    Executive Chairman

    • Tenure: 2.4yrs
    • Compensation: UK£211.00k
  • Chris Mills (64yo)

    Non-Executive Director

    • Tenure: 6.1yrs
    • Compensation: UK£30.00k
  • Michael Roy Roller (53yo)

    Group Finance Director & Director

    • Tenure: 4.8yrs
    • Compensation: UK£223.00k
  • Jay LeCoque (55yo)

    Commercial Director & Executive Director

    • Tenure: 2.4yrs
    • Compensation: UK£80.00k
  • Ian Carruthers

    Non-Executive Director

    • Tenure: 8.4yrs
    • Compensation: UK£30.00k

Company Information

Bioquell plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bioquell plc
  • Ticker: BIQL.F
  • Exchange: OTCPK
  • Founded: 1925
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£131.436m
  • Listing Market Cap: UK£167.087m
  • Shares outstanding: 22.35m
  • Website: https://www.bioquellplc.com

Number of Employees


Location

  • Bioquell plc
  • 52 Royce Close
  • West Portway
  • Andover
  • Hampshire
  • SP10 3TS
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BQELSE (London Stock Exchange)YesOrdinary SharesGBGBPJan 1992
BIQL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
8BQBST (Boerse-Stuttgart)YesOrdinary SharesDEEURJan 1992

Biography

Bioquell plc designs, manufactures, and supplies bio-decontamination and containment equipment, and related products and services in the United Kingdom and internationally. Its bio-decontamination solution ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/01/15 00:21
End of Day Share Price2018/12/14 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.